Literature DB >> 14981759

Analysis of B-lymphocyte differentiation in patients infected with hepatitis C virus.

Anne Fournillier1, Delphine Freida, Thierry Defrance, Philippe Merle, Christian Trépo, Geneviève Inchauspé.   

Abstract

To clarify whether some of the functions of B lymphocytes could be affected during hepatitis C virus (HCV) infection, phenotypic characteristics of B lymphocytes from HCV-infected patients and their capacity to differentiate into immunoglobulins (Ig)-secreting cells were studied. B lymphocytes differentiation was investigated for patients untreated and non-responders (n=9), treated and non-responders (n=6), responders (n=6), long-term responders (n=9) to therapy and seronegative controls (n=14) following in vitro stimulation with S. aureus strain Cowan I mitogen. HCV sequences in purified B lymphocytes were detected by RT-PCR. It was found that HCV-patients harbor a similar mean percentage of B cells and a normal level of naïve B cells (% IgM+/IgD+ cells=79.7 +/- 15.4 for untreated non-responders, 57.1 +/- 22.9 for treated non-responders, 44.3 +/- 29.1 for responders, 75.7 +/- 16 for long-term responders) as compared with controls. It was also found that peripheral blood mononuclear cells (PBMCs) of patients or controls produced similar amounts of IgG, A, and M in vitro. A total of 57% of untreated non-responders versus 17% of treated non-responders were able to produce HCV-specific antibodies. Interestingly, B lymphocytes from PBMCs able to secrete anti-HCV antibodies contained HCV positive strand RNA, although no systematic detection of the negative strand was found. These data suggest that signaling through the B cell receptor (BCR) in B lymphocytes of HCV-infected patients appears normal whatever their response to therapy. The capacity to secrete HCV-specific IgG seemed to be linked to the presence of positive strand RNA rather than virus replication. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981759     DOI: 10.1002/jmv.20039

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells.

Authors:  Jill E Roughan; Kathryn M Reardon; Kristin E Cogburn; Heribert Quendler; Paul J Pockros; Mansun Law
Journal:  Clin Vaccine Immunol       Date:  2012-05-23

Review 2.  Role of hepatitis C virus in B cell lymphoproliferations.

Authors:  Felicia Tucci; Ralf Küppers
Journal:  Virol Sin       Date:  2014-02       Impact factor: 4.327

Review 3.  Immunity and hepatitis C: a review.

Authors:  Rebecca R Terilli; Andrea L Cox
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

4.  Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells.

Authors:  Svetlana Marukian; Christopher T Jones; Linda Andrus; Matthew J Evans; Kimberly D Ritola; Edgar D Charles; Charles M Rice; Lynn B Dustin
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

Review 5.  Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence.

Authors:  Dennis Revie; Syed Zaki Salahuddin
Journal:  Virol J       Date:  2011-07-11       Impact factor: 4.099

6.  Impact of deranged B cell subsets distribution in the development of HCV-related cirrhosis and HCC in type two diabetes mellitus.

Authors:  Fadwa A Abdelwahab; Khaled M Hassanein; Helal F Hetta; Mohamed O Abdelmalek; Asmaa M Zahran; Omnia El-Badawy
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.379

Review 7.  Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII).

Authors:  Giuseppe Sautto; Nicasio Mancini; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-11-08       Impact factor: 5.048

8.  Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+.

Authors:  Agnieszka Pawełczyk; Natalia Kubisa; Joanna Jabłońska; Iwona Bukowska-Ośko; Kamile Caraballo Cortes; Maria Fic; Tomasz Laskus; Marek Radkowski
Journal:  Virol J       Date:  2013-11-26       Impact factor: 4.099

Review 9.  Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases.

Authors:  Youxi Yu; Xiaoju Shi; Xingtong Wang; Ping Zhang; Ou Bai; Yan Li
Journal:  Cell Biosci       Date:  2022-03-12       Impact factor: 7.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.